trending Market Intelligence /marketintelligence/en/news-insights/trending/bqrlj-nhkb2swpgghyonya2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Merck's Keytruda approved as 1st-line treatment of lung cancer in Japan

State Of Singapore Online Video Subscription

Power Forecast Briefing: Capacity Shortfalls to Test the Renewable Energy Transition

Episode 43 - More Change, M&A On Horizon For Equity Research Industry

Cable Nets Struggle With Little Revenue Growth Expanding Programming Budgets


Merck's Keytruda approved as 1st-line treatment of lung cancer in Japan

Japan's Ministry of Health, Labour, and Welfare approved Merck & Co. Inc.'s Keytruda as first- and- second-line treatment of patients with certain types of advanced or recurrent non-small cell lung cancer.

The drug will be manufactured within the country and promoted with Taiho Pharmaceutical Co. Ltd., Merck said.

The drug was also recommended by the European Medicines Agency's Committee for Medicinal Products for Human Use as first-line treatment of metastatic non-small cell lung cancer in adults. Keytruda is already approved for use in melanoma, lung, head and neck cancer in the U.S.